Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is roughly 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts price targets range from a high of $101 to a low of $61.
In its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The retail or Long Term Care segment has offering of prescription drugs and assortment of general merchandise.
The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products as well as similar services, which includes medical, pharmacy, dental, behavioural health, medical control abilities. The Corporate segment involves in offering management as well as administrative services. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.